

| Numéro de catalogue | HF687076 |
|---|---|
| Description |
Pexelizumab (HF687076) is a research-grade recombinant antibody targeting CPAMD4. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Reactivité des espèces | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Espèce hôte | Human |
| Clonalité | Monoclonal |
| Isotype | scFv-nd-nd |
| Système d'expression | Mammalian cells |
| Cible | CPAMD4, C5, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, Complement C5 |
| Niveau d'endotoxines | < 10 EU/mg |
| Pureté | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Numéro d'accès | P01031 |
| Forme | Liquid |
| Tampon de stockage | 0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot. |
| Stabilité et stockage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Noms alternatifs | 5G1.1-SC, 219685-93-5 |
| Contexte | Complement C5 is a ~188 kDa protein. Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. Activated downstream of classical, alternative, lectin and GZMK complement pathways. 1. Rawal, N. et al. (2003) The Journal of biological chemistry 278, 38476-83. PMID: 12878586 2. Rawal, N. et al. (2008) The Journal of biological chemistry 283, 7853-63. PMID: 18204047 3. Heesterbeek, DA. et al. (2019) The EMBO journal 38. PMID: 30643019 4. DiScipio, RG. et al. (1983) The Journal of biological chemistry 258, 10629-36. PMID: 6554279 5. Donado, CA. et al. (2025) Nature 641, 211-221. PMID: 39914456 6. Lan, F. et al. (2025) Nature 638, 490-498. PMID: 39814882 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Pexelizumab.




Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.
Courrier : [email protected]


+86-027-65523339
Bâtiment C, No. 666, Rue Shendunsi, Wuhan, 430206, Chine
中文
English
한국어
日本語
Español
Français
Русский